BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35108788)

  • 21. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the Role of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scanning in the Staging of Patients With Stage IIIB Cervical Carcinoma and the Impact on Treatment Decisions.
    Morkel M; Ellmann A; Warwick J; Simonds H
    Int J Gynecol Cancer; 2018 Feb; 28(2):379-384. PubMed ID: 29324535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
    BMC Cancer; 2011 Oct; 11():452. PubMed ID: 22011459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Groheux D; Giacchetti S; Delord M; de Roquancourt A; Merlet P; Hamy AS; Espié M; Hindié E
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):377-85. PubMed ID: 25432784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Commentary on "Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle." Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam Hospital, Amsterdam, The Netherlands.: BJU Int 2013; 112(6):72934. doi:10.1111/bju.12109. [Epub 2013 Jun 24].
    See WA
    Urol Oncol; 2014 Nov; 32(8):1350. PubMed ID: 25488385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II-III breast cancer patients treated with neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ; Elkhuizen PH
    Breast Cancer Res Treat; 2013 Sep; 141(2):249-54. PubMed ID: 24002735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
    Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
    Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDG-PET/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact.
    Vogsen M; Jensen JD; Christensen IY; Gerke O; Jylling AMB; Larsen LB; Braad PE; Søe KL; Bille C; Ewertz M; Hildebrandt MG
    Breast Cancer Res Treat; 2021 Jan; 185(1):145-153. PubMed ID: 32920740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rate of Distant Metastases on 18F-FDG PET/CT at Initial Staging of Breast Cancer: Comparison of Women Younger and Older Than 40 Years.
    Lebon V; Alberini JL; Pierga JY; Diéras V; Jehanno N; Wartski M
    J Nucl Med; 2017 Feb; 58(2):252-257. PubMed ID: 27587709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma: a prospective study.
    Radhakrishnan V; Kumar R; Malhotra A; Bakhshi S
    J Nucl Med; 2012 Feb; 53(2):191-8. PubMed ID: 22251556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.
    Riegger C; Herrmann J; Nagarajah J; Hecktor J; Kuemmel S; Otterbach F; Hahn S; Bockisch A; Lauenstein T; Antoch G; Heusner TA
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):852-63. PubMed ID: 22392069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
    Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
    J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
    van der Noordaa MEM; van Duijnhoven FH; Straver ME; Groen EJ; Stokkel M; Loo CE; Elkhuizen PHM; Russell NS; Vrancken Peeters MTFD
    Ann Surg Oncol; 2018 Jun; 25(6):1512-1520. PubMed ID: 29511992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
    Koolen BB; Vrancken Peeters MJ; Aukema TS; Vogel WV; Oldenburg HS; van der Hage JA; Hoefnagel CA; Stokkel MP; Loo CE; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography scan on initial evaluation of head and neck squamous cell carcinoma: our experience at a tertiary care center in India.
    Nair S; Mohan S; Nilakantan A; Gupta A; Malik A; Gupta A
    World J Nucl Med; 2015; 14(1):19-24. PubMed ID: 25709540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
    Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.